Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 16/20 | 0.49 |
| ▸ | BTK | Q06187 | 15/20 | 0.49 |
| ▸ | LCK | P06239 | 13/20 | 0.49 |
| ▸ | EGFR | P00533 | 5/20 | 0.49 |
| ▸ | SYK | P43405 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | EML4 | Q9HC35 | 1/20 | 0.42 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18283963 | 0.89 | JAK3 (0.50) | JAK3BTKLCKEGFR | |
| SCHEMBL18283592 | 0.88 | BTK (0.49) | JAK3BTKLCKEGFR | |
| SCHEMBL23081167 | 0.88 | SYK (0.48) | JAK3BTKLCKEGFRSYK | |
| SCHEMBL16763670 | 0.82 | JAK3 (0.61) | JAK3BTKLCKEGFR | |
| SCHEMBL18283767 | 0.79 | SYK (0.53) | EGFRSYKLMNAMAPTALK | |
| SCHEMBL28717580 | 0.79 | ILK (0.53) | EGFRSYKLMNAMAPT | |
| SCHEMBL29557846 | 0.79 | ILK (0.53) | EGFRSYKLMNAMAPT | |
| SCHEMBL18283967 | 0.77 | SYK (0.51) | EGFRSYKLMNAMAPT | |
| SCHEMBL15910662 | 0.77 | SYK (0.46) | EGFRSYKLMNAMAPT | |
| SCHEMBL18283491 | 0.75 | JAK3 (0.57) | JAK3BTKLCKEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210070748-A1 | INHIBITORS OF BRUTONS TYROSINE KINASE | PHARMACYCLICS LLC (US) | 2021-03-11 | — | — | US | disclosed |
| US-20180305348-A1 | INHIBITORS OF BRUTONS TYROSINE KINASE | PHARMACYCLICS LLC | 2018-10-25 | — | — | US | disclosed |
| EP-3310776-A2 | INHIBITORS OF BRUTON'S TYROSINE KINASE | Pharmacyclics LLC (US) | 2018-04-25 | — | — | EP | disclosed |
| WO-2016196776-A2 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS LLC. (US) | 2016-12-08 | — | — | WO | disclosed |
| WO-2016196776-A2 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS LLC. (US) | 2016-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210070748-A1 | INHIBITORS OF BRUTONS TYROSINE KINASE | BTK, LYN, LCK | JAK3 64/4885BTK 1/4885LCK 3/4885 |
| US-20180305348-A1 | INHIBITORS OF BRUTONS TYROSINE KINASE | BTK, LYN, LCK | JAK3 64/4885BTK 1/4885LCK 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.